Last reviewed · How we verify

Janssen R&D Ireland — Portfolio Competitive Intelligence Brief

Janssen R&D Ireland pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
TVR TVR phase 3 Protease inhibitor NS5B polymerase Infectious diseases

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ANRS, Emerging Infectious Diseases · 1 shared drug class
  2. ASST Fatebenefratelli Sacco · 1 shared drug class
  3. Bamrasnaradura Infectious Diseases Institute · 1 shared drug class
  4. Christopher J. McLeod · 1 shared drug class
  5. French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
  6. Hoffmann-La Roche · 1 shared drug class
  7. Janssen-Cilag International NV · 1 shared drug class
  8. Johns Hopkins University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Janssen R&D Ireland:

Cite this brief

Drug Landscape (2026). Janssen R&D Ireland — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-r-d-ireland. Accessed 2026-05-16.

Related